Navigation Links
Breast cancer multigene test helping patients avoid chemotherapy

MAYWOOD, Il. -- A 21-gene test that predicts whether early stage breast cancer patients will benefit from chemotherapy is having a big impact on treatment decisions by patients and doctors alike.

The test caused doctors to change their treatment recommendations in 31.5 percent of cases, while 27 percent of patients changed their treatment decisions. In most such cases, the change by both doctors and patients was to avoid chemotherapy.

The study, lead by Loyola University Health System Medical oncologist Dr. Shelly Lo, is published in the Journal of Clinical Oncology.

The multigene test, Oncotype DX, is made by Genomic Health Inc. The test examines 21 genes from a tumor sample to determine how active they are. A test score between 0 and 100 predicts how likely the cancer is to recur. For women with low scores, chemotherapy is not recommended.

More than 120,000 breast cancer patients have undergone the test since it became commercially available in 2004. The test is intended for patients who have a type of breast cancer, called estrogen receptor-positive that has not spread to the lymph nodes. About 100,000 such cases are diagnosed each year.

"The trend in oncology is towards personalized medicine," Lo said. "We likely will see more tests similar to this one in the future."

The study included 89 breast cancer patients who received the gene test. They were treated by 17 medical oncologists at Loyola, University of Michigan, University of California at Davis and Edward Hospital in Naperville, Il.

Doctors changed treatment decisions for 28 patients. In 20 of these cases, they changed their decision from hormone therapy plus chemotherapy to hormone therapy alone. Twenty-four patients changed their treatment decisions, including nine who dropped chemotherapy.

"This is the first study to show that results from this test simultaneously impact decisions by physicians as well as patients," Lo said. Lo is an assistant professor in the Department of Medicine, Loyola University Chicago Stritch School of Medicine.

Doctors said the test increased their confidence in their treatment recommendations in 76 percent of cases. And in 97 percent of cases, doctors said they would order the test again.

After receiving test results, patients reported they were significantly less conflicted about their decision and felt significantly less anxiety about their situation.

"This test of patients' own breast cancer provides us with greater certainty of who derives benefit from chemotherapy and who can safely avoid it," said senior author Dr. Kathy Albain, professor in the Department of Medicine, Division of Hematology/Oncology, Stritch School of Medicine.

The test costs $3,910, and generally is covered by insurance. Researchers said the test might lower overall costs by avoiding the expense of chemotherapy in some patients.


Contact: Jim Ritter
Loyola University Health System

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced today that ... (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics SL ERP ... partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing commitment ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... Secura Consultants has prided itself for not only fulfilling the needs of advisers ... solutions at an affordable price and providing top-tier customer service. However, there's always ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to ... Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored ... one of twelve colleges and universities in the state of California make the cut. ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and Dr. ... Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial ... conditions present in similar ways and require time-critical intervention to avoid large area heart ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... Cardiac Pacemaker Market Outlook to 2019 - Rise in Cardiac ... " report to their offering. ... Boston scientific and others. --> ... Medtronic, Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Japanese ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology: